This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula I



I

in which

R^2, R^4 denote H, A, Hal, cycloalkyl having 3 to 7 C atoms, CF_3, NO_2, CN, OCF_3, OA, NHA, NA_2, or NH_2,

R^6 is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro- , dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl,

R^3 is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl or 2- or 3-furanyl,

R^1 denotes H or CO_2R^5, $(CH_2)_nCOHet$, CHO, $(CH_2)_nOR^5$, $(CH_2)_nHet$, $(CH_2)_nN(R^5)_2$, CH=N-OA, CH_2CH=N-OA, $(CH_2)_nNHOA$, $(CH_2)_n(R^5)Het$, $(CH_2)_nCH$=N-Het, $(CH_2)_nOCOR'$, $(CH_2)_nN(R^5)CH_2CH_2OR^5$, $(CH_2)_nN(R^5)CH_2CH_2OCF_3$,

$(CH_2)_nN(R^5)C(R^5)OCOR^5$, $(CH_2)_nN(R')CH_2COHet$, $(CH_2)_nN(R^5)CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2N(R')CH_2OCOR'$, $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$, $CH{=}CHCOOR^5$, $CH{=}CHCH_2NR^5Het$, $CH{=}CHCH_2N(R^5)_2$, $CH{=}CHCH_2OR^5$ or $(CH_2)_nN(R^5)Ar$,

R^5 denotes H or A

A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, alkenyl or alkenyloxyalkyl having 2 to 10 C atoms,

Het is 1-piperidyl, 1-piperazyl, 1-(4-methyl)piperazyl, 1-(4-ethyl)piperazinyl, 1-(4-cyclopentyl)piperazinyl, 4-methylpiperazin-1-ylamine, 1-pyrrolidinyl, 1-pyrazolidinyl 1-(2-methyl)pyrazolidinyl, 1-imidazolidinyl or 1-(3-methyl)imidazolidinyl or 4-pyridyl, which is unsubstituted or substituted by one or more CN group, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, or a group of one of the formulae below



	
	
	
	
	
	
	
	

	
	
	
	
	
	
	

	
	
	
	
	
	
	
	

	
	
	
	
	
	
	



Ar denotes a phenyl radical which is unsubstituted or mono or polysubstituted by A and/or Hal, OR^5, $OOCR^5$, $COOR^5$, $CON(R^5)_2$, CN, NO_2, NH_2, $NHCOR^5$, CF_3 or SO_2CH_3,

X denotes CH or N,

n denotes 0, 1, 2, 3, 4 or 5 and

Hal denotes F, Cl, Br or I,

where, in the case that X has the meaning CH, R^2 and R^4 do not simultaneously denote H,

or a salt, enantiomer, or racemate thereof, or a mixture of enantiomers.

2. (Cancelled)

3. (Previously Presented) A compound according to claim 1, in which R^4 denotes H, Hal, CN, A or NO_2.

4. (Previously Presented) A compound according to claim 1, in which R^3 denotes H or alkyl.

5. (Cancelled)

6. (Previously Presented) A compound according to claim 1, in which X has the meaning N.

7. (Previously Presented) A compound of formula IA, IB, IC, ID, IE or IF:



IA



IB



IC



ID



IE



IF

in which

R^3, R^4, R^6 and X have the meanings indicated for the compound of formula I.

8. (Previously Presented) A process for preparing a compound of claim 1, which is of formula IA



IA

in which R^3, R^4, R^6, X and A have the meaning indicated for the compound of formula I

or a salt thereof,

comprising reacting a compound of formula II



II

or an acid-addition salt thereof,

in which R^4, R^6 and X have the meanings indicated for the compound of formula I,

with a compound of formula III



III

in which A and R^3 have the meanings indicated for the compound of formula I,

and/or converting a basic compound of formula IA into one of its salts by treatment with an acid.

9. (Previously Presented) A process for preparing a compound of claim 1, which is of formula IB



IB

in which R^3, R^4, R^6, X and A have the meaning indicated for the compound of formula I or a salt thereof,

comprising reacting a compound of formula II



II

or an acid-addition salt thereof,

in which R^4, R^6 and X have the meanings indicated for the compound of formula I,

with a compound of formula IV



IV

in which A and R^3 have the meanings indicated for the compound of formula I,

and/or converting a basic compound of formula IB into one of its salts by treatment with an acid.

10-13. (Cancelled)

14. (Previously Presented) A pharmaceutical composition comprising at least one compound of the formula I according to claim 1 and/or one of its physiologically acceptable salts, and a pharmaceutically acceptable carrier.

15. (Previously Presented) A process for the preparation of a pharmaceutical composition, comprising combining a compound of the formula I according to Claim 1 and/or one of its physiological acceptable salts into a suitable dosage

form together with at least one solid, liquid or semi-liquid excipient or adjuvant.

16. (Cancelled)

17. (Previously Presented) A compound according to claim 1, in which Het is



18. (Cancelled)

19. (Previously Presented) A method for the *in vitro* inhibition of 5-HT2A receptor, comprising administering to said receptor a compound, salt, enantiomer, racemate or enantiomer mixture of claim 1.

20. (Previously Presented) A compound according to claim 1, in which R^1 denotes denotes H or $(CH_2)_nCOHet$, CHO, $(CH_2)_nOR^5$, $(CH_2)_nHet$, $(CH_2)_nN(R^5)_2$, CH=N-OA, CH_2CH=N-OA, $(CH_2)_nNHOA$, $(CH_2)_n(R^5)Het$, $(CH_2)_nCH$=N-Het, $(CH_2)_nOCOR'$, $(CH_2)_nN(R^5)CH_2CH_2OR^5$, $(CH_2)_nN(R^5)CH_2CH_2OCF_3$, $(CH_2)_nN(R^5)C(R^5)OCOR^5$, $(CH_2)_nN(R')CH_2COHet$, $(CH_2)_nN(R^5)CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2Het$,

$(CH_2)_nN(R^5)CH_2CH_2N(R')CH_2OCOR'$, $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$, $CH{=}CHCOOR^5$, $CH{=}CHCH_2NR^5Het$, $CH{=}CHCH_2N(R^5)_2$, $CH{=}CHCH_2OR^5$ or $(CH_2)_nN(R^5)Ar$.

21. (Previously Presented) A compound according to claim 1, in which R^1 denotes denotes H or CO_2R^5, COHet, CHO, $(CH_2)_nOR^5$, $(CH_2)_nHet$, $(CH_2)_nN(R^5)_2$, CH=N-OA, CH_2CH=N-OA, $(CH_2)_nNHOA$, $(CH_2)_n(R^5)Het$, $(CH_2)_nCH$=N-Het, $(CH_2)_nOCOR'$, $(CH_2)_nN(R^5)CH_2CH_2OR^5$, $(CH_2)_nN(R^5)CH_2CH_2OCF_3$, $(CH_2)_nN(R^5)C(R^5)OCOR^5$, $(CH_2)_nN(R')CH_2COHet$, $(CH_2)_nN(R^5)CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2N(R')CH_2OCOR'$, $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$, $CH{=}CHCOOR^5$, $CH{=}CHCH_2NR^5Het$, $CH{=}CHCH_2N(R^5)_2$, $CH{=}CHCH_2OR^5$ or $(CH_2)_nN(R^5)Ar$.

22. (Previously Presented) A compound according to claim 1, in which R^1 denotes denotes H or $(CH_2)_nHet$, $(CH_2)_nN(R^5)_2$, CH=N-OA, CH_2CH=N-OA, $(CH_2)_nNHOA$, $(CH_2)_n(R^5)Het$, $(CH_2)_nCH$=N-Het, $(CH_2)_nOCOR'$, $(CH_2)_nN(R^5)CH_2CH_2OR^5$, $(CH_2)_nN(R^5)CH_2CH_2OCF_3$, $(CH_2)_nN(R^5)C(R^5)OCOR^5$, $(CH_2)_nN(R')CH_2COHet$, $(CH_2)_nN(R^5)CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2N(R')CH_2OCOR'$, $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$, $CH{=}CHCOOR^5$, $CH{=}CHCH_2NR^5Het$, $CH{=}CHCH_2N(R^5)_2$, $CH{=}CHCH_2OR^5$ or $(CH_2)_nN(R^5)Ar$.

23. (Previously Presented) A compound according to claim 1 or a pharmaceutically acceptable salt thereof.

24. (New) A compound according to claim 1, in which R^3 is thiophen-2-yl or thiophen-3-yl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl or 2- or 3-furanyl.

25. (New) A compound according to claim 1, in which R^3 is 2- or 3-furanyl.